

Active Pharmaceutical Ingredients Catalog

SEPTEMBER 2020

| THERAPY AREA | PRODUCT NAME | FILING STATUS | DR. REDDY'S IP | ORAL | INJ | US DMF | CEP | EU | CDMF | JP DMF | KDMF | RUSSIA | BRAZIL |
|----------------|--|---------------|----------------|------|-----|--------|-----|----|------|--------|------|--------|--------|
| ANTI-DIABETIC | Canagliflozin* | Available | | ● | | ● | | ● | ● | | | △ | ● |
| | Dapagliflozin* | Available | | ● | | ● | | \$ | △ | | ● | △ | ● |
| | Empagliflozin* | Available | | ● | | ● | | \$ | △ | | ● | | △ |
| | Glimepiride | Available | | ● | | ● | ● | | | | | | |
| | Linagliptin | Available | ✓ | ● | | ● | | | | | ● | | |
| | Pioglitazone Hydrochloride | Available | | ● | | ● | ● | ● | ● | ● | | | |
| | Sitagliptin Hydrochloride | Available | ✓ | ● | | ● | | ● | | | ● | ● | △ |
| | Sitagliptin Phosphate* | Available | ✓ | ● | | ● | △ | | △ | | △ | △ | ● |
| | Liraglutide | UD | ✓ | | ● | ● | | △ | | | | | |
| | Semaglutide | UD | ✓ | | ● | | | | | | | | |
| ANTI-INFECTIVE | Gatifloxacin | Available | | | | ● | | | | | | | |
| | Levofloxacin Hemihydrate | Available | | ● | ● | ● | ● | ● | △ | | ● | ● | |
| | Moxifloxacin Hydrochloride | Available | | ● | ● | ● | ● | | ● | | ● | ● | ● |
| | Posaconazole | Available | | ● | ● | ● | | | | | | | |
| | Terbinafine Hydrochloride | Available | | ● | | ● | ● | | | ● | ● | | |
| | Voriconazole | Available | | ● | ● | ● | ● | | ● | | | | |
| | Aviptadil | UD | | | ● | | | | | | | | |
| | HCQS | UD | | ● | | | | | | | | | |
| | Nafamostat | UD | | | ● | | | | | | | | |
| CARDIOVASCULAR | Amlodipine Besylate | Available | | ● | | ● | ● | | △ | ● | ● | ● | |
| | Apixaban | Available | | ● | | ● | | \$ | ● | | ● | △ | ● |
| | Atorvastatin Calcium* | Available | ✓ | ● | | ● | ● | ● | ● | ● | ● | ● | ● |
| | Candesartan | Available | ✓ | ● | | ● | ● | ● | | | | | |
| | Clopidogrel Bisulfate* | Available | ✓ | ● | | ● | ● | ● | ● | ● | ● | ● | ● |
| | Dabigatran Etexilate Mesylate | Available | | ● | | ● | | ● | ● | | △ | △ | △ |
| | Doxazosin Mesylate | Available | | ● | | ● | ● | | | | ● | | ● |
| | Enalapril Maleate | Available | | ● | | ● | ● | | | | ● | ● | |
| | Fondaparinux Sodium | Available | | | ● | ● | | ● | ● | | | △ | |
| | Irbesartan | Available | ✓ | ● | | ● | ● | | | △ | | | |
| | Iron Sucrose (Available for selected markets) | Available | | ● | ● | ● | | | △ | | | | |
| | Lacidipine | Available | | ● | | | | ● | | | | | |

UD - Under Development
 △ - Planned
 \$ - Ready for filing in Europe

* Dr. Reddy's can provide different polymorphs of this product.
 Please contact us for further information.

Disclaimer: No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities.

| THERAPY AREA | PRODUCT NAME | FILING STATUS | DR. REDDY'S IP | ORAL | INJ | US DMF | CEP | EU | CDMF | JP DMF | KDMF | RUSSIA | BRAZIL |
|----------------|---|---------------|----------------|------|-----|--------|-----|----|------|--------|------|--------|--------|
| CARDIOVASCULAR | Losartan Potassium | Available | ✓ | ● | | ● | ● | ● | | ● | | | ● |
| | Metoprolol Succinate | Available | | ● | | ● | | | ● | | | | ● |
| | Prasugrel Hydrochloride | Available | | ● | | ● | | ● | | | | | |
| | Ramipril | Available | | ● | | ● | ● | | ● | | | | |
| | Ranolazine | Available | | ● | | ● | | ● | ● | | | | |
| | Rivaroxaban | Available | | ● | | ● | ● | | ● | △ | | ● | ● |
| | Sacubitril / Valsartan | Available | | ● | | ● | | | ● | | △ | | |
| | Telmisartan | Available | | ● | | ● | ● | ● | | | | | ● |
| | Ticagrelor | Available | ✓ | ● | | ● | △ | ● | ● | | ● | △ | △ |
| | Treprostinil | Available | | ● | ● | ● | | ● | | | | | |
| | Valsartan | Available | ✓ | ● | | ● | ● | ● | ● | ● | ● | △ | ● |
| | Bempedoic Acid | UD | ✓ | ● | | | | | | | | | |
| | Clopidogrel Form 2 | UD | | ● | | | △ | △ | | △ | △ | ● | |
| | Ferric Carboxymaltose (Available for selected markets) | UD | | | ● | | | | | | | | |
| | Ferumoxytol (Available for selected markets) | UD | | | ● | | | | | | | | |
| CNS | Roxadustat | UD | ✓ | ● | | ● | | | | | | | |
| | Asenapine Maleate | Available | ✓ | ● | | ● | | \$ | | | | | |
| | Atomoxetine Hydrochloride | Available | | ● | | ● | | | ● | | | | |
| | Benztropine Mesylate | Available | | ● | ● | ● | | | | | | | |
| | Dimethyl Fumarate | Available | | ● | | ● | | ● | | | | △ | ● |
| | Divalproex Sodium | Available | | ● | | ● | | | △ | | | | ● |
| | Donepezil HCl | Available | | ● | | ● | | ● | | | ● | | |
| | Edaravone | Available | | | ● | ● | | | | | | | |
| | Escitalopram Oxalate | Available | | ● | | ● | ● | ● | | | △ | | |
| | Eslicarbazepine Acetate | Available | | ● | | ● | | ● | | | | | |
| | Eszopiclone | Available | | ● | | ● | | | | | | | |
| | Fingolimod Hydrochloride | Available | | ● | | | | | ● | | | | |
| | Glatiramer Acetate | Available | | | ● | ● | | ● | | | | | ● |
| | Levetiracetam | Available | | ● | ● | ● | ● | | ● | ● | △ | | ● |
| | Lurasidone Hydrochloride | Available | | ● | | ● | | | △ | | | | △ |
| | Memantine Hydrochloride | Available | ✓ | ● | | ● | | \$ | ● | | | | |

UD - Under Development
 △ - Planned
 \$ - Ready for filing in Europe

* Dr. Reddy's can provide different polymorphs of this product.
 Please contact us for further information.

Disclaimer: No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities.

| THERAPY AREA | PRODUCT NAME | FILING STATUS | DR. REDDY'S IP | ORAL | INJ | US DMF | CEP | EU | CDMF | JP DMF | KDMF | RUSSIA | BRAZIL |
|-------------------|-------------------------------|---------------|----------------|------|-----|--------|-----|----|------|--------|------|--------|--------|
| CNS | Olanzapine | Available | | ● | ● | ● | ● | ● | | | | | |
| | Pregabalin | Available | | ● | | ● | ● | ● | ● | △ | △ | ● | ● |
| | Quetiapine Fumarate | Available | | ● | | ● | ● | ● | ● | | ● | | |
| | Risperidone | Available | | ● | ● | ● | ● | | | ● | ● | | ● |
| | Rivastigmine Hydrogen Tartrat | Available | | ● | | ● | ● | ● | | | | | |
| | Tizanidine Hydrochloride | Available | | ● | | ● | ● | ● | | | | | |
| | Vilazodone Hydrochloride | Available | ✓ | ● | | ● | | | | | | | |
| | Ziprasidone Hydrochloride | Available | | ● | ● | ● | ● | ● | | | | | ● |
| | Lumateperone* | UD | ✓ | ● | | | | | | | | | |
| | Siponimod* | UD | ✓ | ● | | | | | | | | | |
| GASTRO-INTESTINAL | Esomeprazole Magnesium* | Available | | ● | | ● | ● | ● | ● | | | | |
| | Famotidine | Available | | ● | ● | ● | ● | | | △ | | | |
| | Lubiprostone | Available | | ● | | ● | | | | | | | |
| | Nizatidine | Available | | ● | | ● | ● | | | ● | ● | | |
| | Obeticholic Acid | Available | ✓ | ● | | ● | | | | | | | |
| | Omeprazole | Available | | ● | ● | ● | ● | | | | ● | | |
| | Omeprazole Magnesium | Available | | ● | | ● | | ● | | | | | |
| | Pantoprazole Sodium | Available | | ● | ● | ● | ● | ● | ● | | | | |
| | Rabeprazole Sodium* | Available | | ● | | ● | ● | ● | | △ | | | |
| | Linacotide | UD | ✓ | ● | | | | | | | | | |
| MUSCULO-SKELETAL | Apremilast* | Available | | ● | | ● | | § | ● | | △ | △ | |
| | Estradiol | Available | | ● | | | | | | | | | |
| | Raloxifene Hydrochloride | Available | | ● | | ● | ● | | △ | | ● | | |
| | Abaloparatide | UD | | | ● | △ | | | | | | | |
| ONCOLOGY | Abiraterone Acetate | Available | | ● | | ● | | ● | △ | △ | △ | ● | ● |
| | Azacitidine | Available | ✓ | ● | ● | ● | | ● | ● | ● | ● | ● | ● |
| | Bendamustine Hydrochloride | Available | | | ● | ● | | ● | △ | △ | | | △ |
| | Bortezomib | Available | | | ● | ● | | ● | ● | | | ● | |
| | Cabazitaxel | Available | | | ● | ● | | ● | | | | ● | ● |
| | Capecitabine | Available | | ● | | ● | ● | | ● | | | ● | ● |
| | Carfilzomib | Available | ✓ | | ● | ● | | | | | | | |

UD - Under Development
 △ - Planned
 § - Ready for filing in Europe

* Dr. Reddy's can provide different polymorphs of this product.
 Please contact us for further information.

Disclaimer: No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities.

| THERAPY AREA | PRODUCT NAME | FILING STATUS | DR. REDDY'S IP | ORAL | INJ | US DMF | CEP | EU | CDMF | JP DMF | KDMF | RUSSIA | BRAZIL |
|--------------|--|---------------|----------------|------|-----|--------|-----|----|------|--------|------|--------|--------|
| ONCOLOGY | Dasatinib (Available for selected markets) | Available | ✓ | ● | | ● | | ● | | | | | ● |
| | Decitabine | Available | | | ● | ● | | | | | ● | | ● |
| | Docetaxel | Available | | | ● | ● | ● | ● | | | | | |
| | Enzalutamide* | Available | | ● | | ● | | | ● | | | △ | ● |
| | Gemcitabine Hydrochloride | Available | | | ● | ● | ● | | ● | ● | ● | ● | ● |
| | Granisteron | Available | | | ● | ● | | ● | | | ● | | |
| | Ibandronate Sodium | Available | | ● | ● | ● | | ● | | | ● | ● | ● |
| | Ibrutinib* | Available | ✓ | ● | | ● | | | △ | | | | |
| | Lenalidomide* | Available | ✓ | ● | | ● | | ● | ● | | | ● | △ |
| | Lenvatinib* | Available | ✓ | ● | | ● | | | △ | | | | |
| | Letrozole | Available | | ● | | ● | ● | | | ● | | | |
| | Lomustine | Available | | ● | | ● | ● | | | | | ● | |
| | Nilotinib Hydrochloride* (Available for selected markets) | Available | ✓ | ● | | ● | | \$ | | | | | |
| | Ondansetron Base* | Available | | ● | ● | | | | | | | | |
| | Ondansetron Hydrochloride | Available | | ● | ● | ● | ● | ● | △ | ● | ● | | ● |
| | Palbociclib | Available | ✓ | ● | | ● | | | △ | | | | |
| | Palonosetron Hydrochloride | Available | ✓ | | ● | ● | | ● | | | ● | | |
| | Pemetrexed Disodium* | Available | ✓ | | ● | ● | ● | ● | ● | ● | | ● | ● |
| | Pemetrexed Ditromethamine | Available | ✓ | | ● | ● | | ● | | | | | |
| | Plerixafor | Available | | | ● | ● | | \$ | | | | | |
| | Pomalidomide | Available | | ● | | ● | | | | | | | |
| | Venetoclax | Available | ✓ | ● | | ● | | | | | | | |
| | Zoledronic Acid | Available | | | ● | ● | ● | ● | | | | ● | |
| | Apalutamide* | UD | ✓ | ● | | ● | | | | | | | |
| | Eribulin (Available for selected markets) | UD | ✓ | | ● | △ | | | | | | | |
| | Fosaprepitant | UD | | | ● | △ | | | | | | | |
| | Midostaurin* | UD | ✓ | ● | | ● | | | | | | | |
| | Olaparib* | UD | | ● | | △ | | | | | | | |
| | Pazopanib | UD | | ● | | △ | | | | | | | |
| | Ruxolitinib Phosphate* | UD | ✓ | ● | | | | | | | | | |

UD - Under Development
△ - Planned
\$ - Ready for filing in Europe

* Dr. Reddy's can provide different polymorphs of this product.
Please contact us for further information.

Disclaimer: No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities.

| THERAPY AREA | PRODUCT NAME | FILING STATUS | DR. REDDY'S IP | ORAL | INJ | US DMF | CEP | EU | CDMF | JP DMF | KDMF | RUSSIA | BRAZIL |
|-----------------|--|---------------|----------------|------|-----|--------|-----|----|------|--------|------|--------|--------|
| PAIN MANAGEMENT | Ketorolac Tromethamine | Available | | ● | ● | ● | ● | | | | ● | ● | △ |
| | Naproxen | Available | | ● | | ● | ● | | ● | ● | ● | ● | |
| | Naproxen Sodium | Available | | ● | | ● | ● | | | | ● | ● | ● |
| | Naratriptan Hydrochloride | Available | | ● | | ● | | ● | | | | | ● |
| | Sumatriptan Succinate | Available | | ● | ● | ● | ● | | | ● | | ● | |
| | Elagolix Sodium | UD | ✓ | ● | | △ | | | | | | | |
| RESPIRATORY | Cetirizine Dihydrochloride | Available | | ● | | ● | ● | | | ● | ● | ● | |
| | Desloratadine | Available | | ● | | ● | ● | ● | | | | | |
| | Fexofenadine Hydrochloride* | Available | | ● | | ● | △ | ● | △ | △ | △ | | |
| | Levocetirizine Dihydrochloride | Available | | ● | | ● | | ● | | | ● | | ● |
| | Montelukast Sodium | Available | | ● | | ● | ● | ● | ● | | | | ● |
| | Zafirlukast | Available | | ● | | ● | | | | | | | |
| UROLOGY | Dutasteride | Available | | ● | | ● | | ● | ● | ● | ● | ● | |
| | Eliglustat Hemitartrate | Available | | ● | | ● | | | | | | | |
| | Febuxostat | Available | | ● | | ● | | § | | | ● | | |
| | Finasteride* | Available | | ● | | ● | ● | | △ | ● | ● | ● | △ |
| | Mirabegron* | Available | ✓ | ● | | ● | | § | ● | | ● | | ● |
| | Testosterone | Available | | | | ● | | § | | | | | |
| OTHERS | Cinacalcet Hydrochloride | Available | | ● | | ● | | ● | ● | | | ● | ● |
| | Icatibant Acetate | Available | | | ● | ● | | ● | | | | | |
| | Lifitegrast | Available | ✓ | | | ● | | | | | | | |
| | Lorcaserin Hydrochloride | Available | | ● | | ● | | | | | | | ● |
| | Permethrin | Available | | | | ● | △ | ● | | | | | |
| | Sugammadex Sodium | Available | | | ● | ● | | ● | ● | | ● | △ | ● |
| | Diroximel Fumarate | UD | ✓ | ● | | △ | | | | | | | |
| | Ivermectin | UD | | | ● | | | | | | | | |
| | Lasmiditan | UD | | ● | | | | | | | | | |
| | Pidotimod | UD | | ● | | | | | | | | | |
| | Remdesivir (Available for selected markets) | UD | | ● | | | | | | | | | |
| | Tofacitinib | UD | | ● | | | | | | | | | |
| | Varenicline Tartrate | UD | | ● | | △ | | | | | | | |

UD - Under Development
△ - Planned
§ - Ready for filing in Europe

* Dr. Reddy's can provide different polymorphs of this product.
Please contact us for further information.

Disclaimer: No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities.

OTHER PIPELINE PRODUCTS

| Therapy Area | Product Name | Dr. Reddy's IP | Oral | Inj |
|-----------------------------------|---------------------|----------------|------|-----|
| Antimigraine | Rimegepant | | ● | |
| Oncology | Alpelisib | | ● | |
| | Dacomitinib | | ● | |
| | Erdafitinib | ✓ | ● | |
| Oncology & Obstetrics/ Gynecology | Relugolix | ✓ | ● | |
| Metabolic | Tafamidis Free Acid | ✓ | ● | |
| | Tafamidis Meglumine | ✓ | ● | |

Development timeline to be checked with the Sales Manager

September 2020

Disclaimer: No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities.

Re-imagine API sourcing with Dr. Reddy's 

Contact us for more information at api@drreddys.com



Sign up for our customer service portal on
<https://api.drreddys.com/customer/signup>

OR

scan the
QR code



api.drreddys.com | api@drreddys.com